What is Viberzi?
Viberzi is a medication used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. Its active ingredient is eluxadoline, which works as a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist. This mechanism of action helps to reduce the symptoms of IBS-D, including abdominal pain and diarrhea.
Viberzi was approved by the U.S. Food and Drug Administration (FDA) in 2015 and is classified as a Schedule IV controlled substance. However, in 2017, the FDA issued a warning stating that Viberzi should not be used in patients who do not have a gallbladder, due to an increased risk of pancreatitis. Viberzi is available in tablet form, and the dosage may vary depending on the individual patient's needs.
In terms of costs, Viberzi is a relatively expensive medication with an average cost of nearly $1,300 for 60 tablets. There have also been concerns about the potential risks associated with the use of Viberzi, such as addiction and misuse.
It is important to consult with a healthcare professional before taking any medication, including Viberzi. They can evaluate an individual's specific health needs and medical history to determine whether Viberzi is a suitable treatment option and can provide guidance on proper use and potential side effects.
Frequently Asked Questions about viberzi
The active ingredient in VIBERZI is eluxadoline, a mu-opioid receptor agonist.
Viberzi (eluxadoline) is a prescription drug marketed by Allergan for the treatment of irritable bowel syndrome with diarrhea (IBS-D). It belongs to a class of drugs known as mu-opioid receptor agonists.
Eluxadoline is marketed by Patheon Pharmaceuticals and marketed as Viberzi. The brand name for rifaximin is Xifaxan. Both drugs are approved for treatment of IBS-D. Eluxadoline: 100 mg twice daily taken with food.
Ironwood Pharmaceuticals, Inc. - Ironwood and Allergan Enter Agreement to Co-Promote VIBERZI for Irritable Bowel Syndrome with Diarrhea (IBS-D) in the U.S.
VIBERZI is a prescription medicine that is FDA approved for daily use in adults with IBS‑D to reduce abdominal pain and diarrhea at the same time. Taken every day as prescribed, VIBERZI may provide relief by making stools less loose and watery and reducing abdominal pain.
This medication is used to treat a certain stomach/abdominal disorder (irritable bowel syndrome with diarrhea, or IBS-D). It works by slowing down the motion in your gut. This effect helps lessen symptoms such as belly pain and diarrhea.
ELUXADOLINE (ee LUX ah dol ine) treats irritable bowel syndrome (IBS) with diarrhea. It works by slowing down an overactive bowel, which decreases the number of bowel movements you have. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.
VIBERZI is a prescription medicine that is FDA approved for daily use in adults with IBS‑D to reduce abdominal pain and diarrhea at the same time. Taken every day as prescribed, VIBERZI may provide relief by making stools less loose and watery and reducing abdominal pain.
Eluxadoline is used to treat irritable bowel syndrome with diarrhea (IBS-D; a condition that causes stomach pain, cramping, or loose or watery stools) in adults. Eluxadoline is in a class of medications called mu-opioid receptor agonists. It works by decreasing bowel activity.
Eluxadoline Tablets. Eluxadoline is a medication that treats diarrhea caused by irritable bowel syndrome. IBS causes uncomfortable or painful abdominal symptoms. This medication comes in a tablet form that you can take by mouth with a glass of water as directed.
The cost for Viberzi oral tablet 75 mg is around $1,615 for a supply of 60 tablets, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
For the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in adults, the rate of composite response was numerically greater with VIBERZI than with placebo at 3 and 6 months. VIBERZI responders had dual-symptom relief.
